Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Dynavax shares set to rise on “encouraging’ results of cancer drug

Monday, April 16, 2018 6:41
% of readers think this story is Fact. Add your two cents.

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) are set to climb after MarketWatch said the company reported its immune-oncology drug showed “promising” response rate in treating head and neck cancers.

The stock rose 14% to US$22.44 in pre-market trading.

Dynavax released data in an abstract at the American Association for Cancer research meeting, MarketWatch said.

The SD-101 drug “showed a promising 40%” overall response rate “indicative of potential activity in the difficult-to-treat setting of head and neck cancers,” the report said, citing RBC Capital Markets analyst Brian Abrahams.




Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories


Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.